Europe Therapeutic Vaccines Market
Europe Therapeutic Vaccines Market is growing at a CAGR of 12.7% to reach US$ 14,76,492.99 thousand by 2031 from US$ 6,39,242.94 thousand in 2024 by Product, Technology, End User.

Published On: Sep 2025

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Europe Therapeutic Vaccines Market
Free Sample Buy Now
Europe Therapeutic Vaccines Market

At 12.7% CAGR, Europe Therapeutic Vaccines Market is Projected to be Worth US$ 14,76,492.99 Thousand by 2031, says Business Market Insights

According to Business Market Insights' research, the Europe therapeutic vaccines market was valued at US$ 6,39,242.94 thousand in 2024 and is expected to reach US$ 14,76,492.99 thousand by 2031, registering a CAGR of 12.7% from 2024 to 2031. Rising prevalence of chronic conditions and extending product pipeline are among the critical factors attributed to drive the Europe therapeutic vaccines market. 

As the global demand for innovative treatment options rises, the therapeutic vaccines sector has witnessed robust investments and advancements in vaccine development, driven largely by the rising number of clinical candidates progressing through various stages of development. Innovative R&D efforts in biotechnology are yielding cutting-edge therapeutic vaccines that target various diseases, particularly newer infections and chronic ones such as cancer. Moderna's mRNA-4157 is currently in phase 2 trials, with early-stage results showing promising potential in combination with checkpoint inhibitors for melanoma treatment. In addition to oncology, the therapeutic vaccine pipeline is also growing in areas such as autoimmune diseases and infectious diseases (HIV, HPV, and HBV infections).

Several companies are investing in scientific and technical excellence to develop and introduce new therapeutic vaccines. With the expanding pipeline of vaccine candidates targeting diverse diseases, therapeutic vaccines hold immense potential to address unmet medical needs. Below is the product pipeline for therapeutic vaccines targeting various conditions:

Vaccine type

Vaccine Formulation

Phase/status

Condition

Bacterial vector vaccine

ADXS11–001 (attenuated live Listeria Encoding HPV 16 E7 vector)

Phase I/II

  • Cervical carcinoma
  • Cervical cancer
  • Anal cancer
  • Rectal cancer

Peptide/protein vaccine

ISA101 (nine HPV-16 E6 and four HPV-16 E7 synthetic peptides with Montanide ISA51)

Phase II

  • Solid tumors

Personalized peptide vaccine

NeoVax (neoantigen + Poly-ICLC)

Phase I

  • Kidney cancer

mRNA-based neoantigen vaccine

mRNA-4157 (lipid-encapsulated RNA)

Phase I/II

  • Solid tumors
  • Melanoma

DNA vaccine

VGX-3100 (plasmid encoding E6 and E7 of HPV16/18)  

Phase I/II

  • Head and neck squamous cell cancer
  • Cervical cancer

Virus-like particle

NASVAC (HBsAg, HBcAg)

Phase III

  • HBV infection

Protein vaccine

Theravax (DV-601, consisting of HBsAg, HbcAg, and saponin-based ISCOMATRIX adjuvant)

Phase II

  • Chronic HBV infection

mRNA vaccine

iHIVARNA (consisting of HIV immunogen sequence and a mixture of activation molecules)

Phase I

  • HIV infection

Viral vector vaccines

  • AdCh3NSmut/Ad6NSmut (encoding HCV proteins)
  • TG4040 (expressing NS3/4/5B proteins)

Phase I

  • HCV infection

DNA vaccine

pNGVL4a-Sig/E7(detox)/HSP70 (HPV16 E7)

Phase I

  • HPV infection

With strong ongoing clinical trials, the market's prospects are expected to expand, offering new treatment options for patients worldwide and addressing unmet medical needs in areas where current treatments are ineffective. Thus, a strong pipeline of candidates for therapeutic vaccines signifies lucrative growth opportunities for the therapeutic vaccines market.

On the contrary, regulatory challenges hampers the growth of Europe Therapeutic Vaccines Market.

Based on product, the Europe therapeutic vaccines market is segmented into cancer vaccine, infectious disease vaccine, and others. The cancer vaccine segment held 100.0% market share in 2024, amassing US$ 6,39,242.94 million. It is projected to garner US$ 14,43,283.78 million by 2031 to register 12.3% CAGR during 2024–2031.

By technology, the Europe therapeutic vaccines market is bifurcated into allogenic vaccine and autologus vaccine. The autologus vaccine segment held 67.4% share of Europe therapeutic vaccines market in 2024, amassing US$ 4,30,799.76 million. It is projected to garner US$ 9,89,082.71 million by 2031 to expand at 12.6% CAGR from 2024 to 2031.

In terms of end user, the Europe therapeutic vaccines market is categorized into hospital, Clinics, and others. The hospital segment held 61.9% share of Europe therapeutic vaccines market in 2024, amassing US$ 3,95,599.89 million. It is projected to garner US$ 9,31,266.08 million by 2031 to expand at 13.0% CAGR from 2024 to 2031.

Based on country, the Europe therapeutic vaccines market is categorized into the Germany, the UK, France, Italy, Spain, and the rest of Europe. Our regional analysis states that Germany captured 29.2% share of Europe therapeutic vaccines market in 2024. It was assessed at US$ 1,86,586.20 million in 2024 and is likely to hit US$ 4,46,909.84 million by 2031, registering a CAGR of 13.3% during 2024 to 2031.

Key players operating in the therapeutic vaccines market are Dendreon, BioNTech SE, Serum Institute of India Pvt. Ltd, Merck & Co Inc, Amgen Inc, ISA Pharmaceuticals BV, INOVIO Pharmaceuticals Inc, Transgene SA, THERAVECTYS SA, and CureVac SE among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com